Pilot corpus: NIH-funded biomedical datasets. Any DOI can be scored on demand — network effects sharpen as coverage grows.

Brain-Restricted mTOR Inhibition with Binary Pharmacology

bioRxiv (Cold Spring Harbor Laboratory)(2020)10.1101/2020.10.12.336677Source: DataRank Database

Brain-Restricted mTOR Inhibition with Binary Pharmacology is a research paper published in bioRxiv (Cold Spring Harbor Laboratory) (2020). On theSindex it has a DataRank of 0. It has been cited 10 times.

N/A

0DataRank · unranked

Scored on demand from live citation data

Open Access10 citations

Download PDF

Cite:

DataRank reads this dataset's downstream impact straight off the citation graph — no black box, no proprietary weighting. How is this computed?

›Methodology & internals

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Pipeline:MetadataData-paper checkEnrichmentCitation networkScoring

Enrichment:Funding (4 grants)OA: greenTopics (58)IDs (PubMed)SDGs (1)

FAIR Checklist

Context only (not used in score)

Findable (1/2)

Has DOI

Accessible (1/2)

Open Access

Interoperable (0/2)

Reusable (0/3)

FAIR checklist signals are shown for context only and do not affect DataRank scoring.

Run a calibrated FAIR evaluation for this paper →

We only score data papers we can read in full — never from an abstract alone.

Authors (6)

Qi-Wen Fan,Xujun Luo ORCID,Kevin Lou ORCID,William A. Weiss ORCID,Kevan M. Shokat ORCID

Live enrichment

PubMed:36104566

National Institutes of Health

Grant: 1R01DC001007-01

ONTOGENY OF COCHLEAR NUCLEUS RESPONSES TO AMINO ACIDS

National Institutes of Health

Grant: 5F30CA239476-03

Investigating functional interactions with KRAS G12C inhibition

National Institutes of Health

Grant: 5U01CA217864-03

Integrating targeted and immunotherapy to treat genetically heterogeneous cancers

National Institutes of Health

Grant: 5R01CA221969-05

Improving the efficacy of mTOR inhibition

greenLicense: cc-by-nc-nd

repositoryhttps://www.biorxiv.org/content/biorxiv/early/2020/10/12/2020.10.12.336677.full.pdf

publisherhttps://syndication.highwire.org/content/doi/10.1101/2020.10.12.336677

https://doi.org/10.1038/s41586-022-05213-y

https://doi.org/10.21203/rs.3.rs-92256/v1

https://doi.org/10.1101/2020.10.12.336677

Fields of Study

0301 basic medicine0303 health sciences03 medical and health sciences

Keywords

Ligands (mesh)General Science & Technology (science-metrix)Biological PsychologyTacrolimus Binding Protein 1ALigandsBrain Disorders (rcdc)Psychology32 Biomedical and Clinical Sciences (for-2020)Neurosciences (rcdc)Cancer3214 Pharmacology and Pharmaceutical Sciences (for-2020)Cancer (rcdc)Brain Cancer (rcdc)Humans (mesh)52 Psychology (for-2020)TOR Serine-Threonine KinasesGeneric health relevance (hrcs-hc)BrainPharmacology and Pharmaceutical SciencesTOR Serine-Threonine Kinases (mesh)MTOR InhibitorsCombination (mesh)5.1 PharmaceuticalsGlioblastoma (mesh)Combination5202 Biological Psychology (for-2020)Drug Therapy, CombinationSirolimus (mesh)Macrocyclic CompoundsGeneral Science & Technology34 Chemical Sciences (for-2020)610Tacrolimus Binding Protein 1A (mesh)MTOR Inhibitors (mesh)ArticleRare Diseases (rcdc)Medicinal and Biomolecular ChemistryBrain (mesh)Rare DiseasesDrug Therapy5.1 Pharmaceuticals (hrcs-rac)Xenograft Model Antitumor Assays (mesh)HumansSirolimusBiomedical and Clinical Sciences3404 Medicinal and Biomolecular Chemistry (for-2020)NeurosciencesXenograft Model Antitumor AssaysBrain DisordersBrain CancerOrphan DrugChemical SciencesOrphan Drug (rcdc)Generic health relevanceGlioblastoma

Sustainable Development Goals

SDG 3: 3. Good health